<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth S Klings, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with pulmonary hypertension (PH) due to diffuse lung disease (eg, chronic obstructive pulmonary disease, interstitial lung disease, or overlap syndromes) or conditions that cause hypoxemia (eg, obstructive sleep apnea, alveolar hypoventilation disorders) are classified as having group 3 PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>).</p><p>The prevalence, pathogenesis, and diagnosis of PH due to lung disease and/or hypoxemia are presented here. The treatment and prognosis of patients with group 3 PH are reviewed separately. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H46193899"><span class="h1">CLASSIFICATION AND DEFINITIONS</span><span class="headingEndMark"> — </span>The classification and definitions of PH and cor pulmonale are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Patients with PH are classified into five groups based upon etiology [<a href="#rid1">1</a>]. Patients in group 1 are considered to have pulmonary <strong>arterial</strong> hypertension (PAH; also sometimes referred to as pre-capillary PH), whereas patients in group 2 (due to left-sided heart disease), group 3 (due to chronic lung disorders and hypoxemia), group 4 (due to pulmonary artery obstructions), and group 5 (due to unidentified or mixed mechanisms) are considered to have PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). When all five groups are discussed collectively, the term PH is used. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension</strong> – PH is defined as a mean pulmonary artery pressure (mPAP) &gt;20 mmHg at rest, measured by right heart catheterization [<a href="#rid1">1</a>]. PH is considered severe if mPAP is ≥35 mmHg or the mPAP is &gt;20 mmHg with an elevated right atrial pressure (&gt;14 mmHg) and/or the cardiac index is &lt;2 L/min/m<sup>2</sup> [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cor pulmonale</strong> – Cor pulmonale is a complication of PH. Cor pulmonale refers to PH-induced altered structure (eg, hypertrophy or dilatation) and/or impaired function of the right ventricle (RV) that is associated with chronic lung disease and/or hypoxemia (ie, group 3 PH). While some experts disagree on the inclusion of RV dysfunction due to pulmonary vascular disease (ie, group 1 PAH), most agree that RV dysfunction due to left-sided heart disease or congenital heart disease is <strong>not</strong> considered cor pulmonale [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H680313403"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Accurate estimations of PH in patients with chronic lung disease and/or hypoxemia have been difficult to ascertain due to heterogeneity in the type and severity of underlying lung disease and study differences in the definitions of PH (eg, mean pulmonary artery pressure [mPAP] &gt;20 mmHg or ≥25mmHg) as well as techniques (echocardiography or right heart catheterization [RHC]) used to assess PH. In general, most patients in group 3 PH have <strong>mild to moderate</strong> elevations in mPAP (20 to 35 mmHg). Less than 5 percent have severe PH, which is typical of group 1 pulmonary arterial hypertension (PAH).</p><p>Group 3 PH appears to be more prevalent in older adults. In one series of patients ≥65 years with PH, group 3 PH occurred in 14 percent, while 28 percent had group 2 PH and 17 percent had mixed group 2/3 PH [<a href="#rid4">4</a>].</p><p>Group 3 PH can be due to obstructive lung disease, restrictive lung disease, lung disorders with mixed restriction and obstruction, hypoventilation syndromes (eg, sleep apnea), hypoxia without lung disease (eg, high altitude), and developmental lung disorders. The prevalence in individual disorders is discussed in the sections below.</p><p class="headingAnchor" id="H2537310770"><span class="h2">Chronic obstructive pulmonary disease</span><span class="headingEndMark"> — </span>Several studies report that PH is generally mild in patients with chronic obstructive pulmonary disease (COPD) and has a prevalence that ranges from 25 to 90 percent [<a href="#rid3">3,5-20</a>]. However, data are biased since they are derived from patients with severe COPD undergoing lung transplant evaluation (right heart catheterization [RHC] data, which are more accurate than echocardiography, are more readily available and justified in this population). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 374 patients with advanced lung disease (transplant candidates), most of whom had COPD, the prevalence of PH was 25 percent by RHC [<a href="#rid7">7</a>]. Almost half of the study population were misclassified as having PH by echocardiography (sensitivity and specificity of 85 and 55 percent, respectively) suggesting that echocardiography may be less useful diagnostically in those with severe lung disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One retrospective review of 156 patients with advanced lung disease, most of whom had COPD, reported that two-thirds had right ventricle (RV) dysfunction [<a href="#rid9">9</a>]. PH was in the mild range with a mean mPAP of 25 mmHg, but was markedly lower than that seen in those with group 1 PAH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), in whom the mean mPAP was 50 mmHg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective study of 215 patients with COPD undergoing transplant evaluation, half had PH, with a mean mPAP of 27 mmHg [<a href="#rid10">10</a>]. Only 10 percent of patients had a mPAP &gt;35 mmHg and less than 4 percent had a mPAP &gt;45 mmHg. Data from the Organ Procurement and Tissue Network database showed a similar prevalence of mild and severe PH [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, in those undergoing evaluation for lung reduction surgery for emphysema, a higher prevalence of 91 percent was reported but the prevalence of severe PH was similar [<a href="#rid11">11</a>].</p><p></p><p>The prevalence is likely lower in those with mild to moderate COPD but RHC data are less readily available in this population and most estimates are derived from echocardiography [<a href="#rid13">13-19</a>]. Resting PH ranges from 20 to 60 percent in those with moderate COPD [<a href="#rid16">16-18</a>] with the higher end of this range consistently noted during exercise [<a href="#rid18">18,19</a>]. PH can develop over time with one study reporting that 25 percent of patients with moderate COPD and normal resting mPAP developed PH (defined as mPAP &gt;20 mmHg on RHC) over a seven year period [<a href="#rid20">20</a>].</p><p>The severity of PH appears to correlate with the magnitude of hypoxemia, hypercapnia, and airflow obstruction, as suggested by a study that found right RV hypertrophy in 40 percent of patients with a forced expiratory volume in one second (FEV<sub>1</sub>) &lt;1 L and 70 percent of patients with a FEV<sub>1</sub> &lt;0.6 L [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2002001204"><span class="h2">Interstitial lung disease</span><span class="headingEndMark"> — </span>The reported prevalence of interstitial lung disease (ILD)-associated PH ranges from 30 to 90 percent and similar to patients with COPD, PH is generally mild to moderate and rarely severe. Rates vary depending upon the population studied:</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic pulmonary fibrosis (IPF) – An mPAP of ≥25 mmHg is present in 8 to 15 percent at initial evaluation of IPF, in 30 to 50 percent of advanced cases, and in over 60 percent of end-stage IPF patients (mPAP mostly assessed by RHC) [<a href="#rid21">21-24</a>]. In the largest of these studies, 46 percent of patients with advanced ILD had mPAP ≥25 mmHg but only 9 percent had mPAP &gt;40 mmHg (ie, severe PH) [<a href="#rid23">23</a>]. A decreased diffusing capacity may predict PH [<a href="#rid25">25</a>], although spirometric abnormalities correlate poorly [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/14870.html" rel="external">"Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Connective tissue diseases (CTDs) – The prevalence of PH alone or PH in combination with ILD varies widely among CTDs [<a href="#rid28">28-37</a>]. Most data come from studies in patients with systemic sclerosis [<a href="#rid36">36,38</a>]. The prevalence of PH in patients with systemic sclerosis is estimated on average to range from 10 to 15 percent, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumoconioses – PH can complicate pneumoconioses, including asbestosis, coal worker's pneumoconiosis, silicosis, and unspecified pneumoconiosis [<a href="#rid39">39-41</a>]. In general, although rates are unknown, the severity of the parenchymal disease may correlate with severity of the PH [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/d/html/4307.html" rel="external">"Asbestos-related pleuropulmonary disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined pulmonary fibrosis and emphysema (CPFE) – CPFE is a syndrome where clinical, radiologic, and pathologic features of both fibrosis and emphysema exist in the same patient [<a href="#rid42">42</a>]. PH in CPFE is a common complication that is thought to be more frequent and severe when compared with COPD and ILD alone. In an observational cohort of 110 patients with IPF, compared with those with IPF alone, the systolic pulmonary artery pressure was higher in the 31 patients who had CPFE (82 versus 57 mmHg) [<a href="#rid43">43</a>]. Another study of 40 patients with CPFE with PH reported a mPAP in this population that was in the severe range (40 mmHg) [<a href="#rid44">44</a>]. These patients are often characterized by a severe reduction in their diffusing capacity (DLCO) in the setting of a normal or near normal forced expiratory volume in one second and forced vital capacity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphangioleiomyomatosis (LAM) – LAM was originally classified as group 5 but is now classified as group 3. Rare case reports describe low rates of PH in patients with lymphangioleiomyomatosis (typically &lt;7 percent), the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Other'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others – Other ILDs associated with PH are actually classified in group <strong>5</strong> PH:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sarcoidosis – PH can exist in any patient with sarcoidosis, but is most common among patients with advanced disease [<a href="#rid45">45-50</a>]. In a prospective study of 212 patients with sarcoidosis, 6 percent had PH (estimated sPAP ≥40 mmHg on echocardiography) [<a href="#rid46">46</a>]. In contrast, another prospective study that included 363 patients with severe sarcoidosis (lung transplantation candidates), PH was detected in 74 percent [<a href="#rid45">45</a>]. One large European cohort suggested a prevalence of only 3 percent in White individuals with sarcoidosis [<a href="#rid51">51</a>]. PH correlated with the need for supplemental oxygen, but not spirometric results or treatment with glucocorticoids. Mechanisms involved include fibrotic obliteration of pulmonary vessels, extrinsic compression of pulmonary vessels by lymphadenopathy, granulomatous involvement of small pulmonary vessels, and pulmonary veno-occlusive-like lesions, left ventricular dysfunction, or portopulmonary hypertension from liver disease [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary Langerhans cell histiocytosis (PLCH) – PH associated with PLCH tends to be more common and may be more severe than PH associated with other lung diseases (eg, emphysema, IPF) [<a href="#rid26">26</a>]. A retrospective study of 17 patients with PLCH reported that 89 percent had an estimated sPAP on echocardiography &gt;35 mmHg and 53 percent had an estimated sPAP &gt;50 mmHg; PH correlated with the severity of lung function [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Others – PH may complicate cystic fibrosis, bronchopulmonary dysplasia, hypersensitivity pneumonitis, and possibly lung cancer [<a href="#rid54">54-57</a>]. (See  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Pulmonary hypertension'</a> and  <a class="medical medical_review" href="/d/html/115896.html" rel="external">"Pulmonary hypertension associated with bronchopulmonary dysplasia"</a> and  <a class="medical medical_review" href="/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1538627010"><span class="h2">Sleep disordered breathing</span><span class="headingEndMark"> — </span>Most studies suggest PH rates of 20 to 30 percent in patients with obstructive sleep apnea (OSA) [<a href="#rid58">58-61</a>], although estimates may be inaccurate since many patients also have COPD and/or left-sided heart disease, which can also contribute to the development of PH. In most cases PH is mild. (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Complications'</a>.)</p><p>One large review of eight studies reported prevalence rates of PH in OSA that ranged from 17 to 70 percent, and an average mPAP level of 30 mmHg [<a href="#rid58">58</a>]. However, in one study that reported the highest rates of PH (70 percent), most patients had a component of left-sided pulmonary venous hypertension (ie, group 2 PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>)) and when this study was removed from the analysis, the prevalence of PH decreased to 22 percent. These lower rates are similarly reflected in other studies [<a href="#rid60">60</a>].</p><p>Rates may be higher in those with coexistent obesity hypoventilation syndrome with one study reporting a prevalence of 58 percent [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/7698.html" rel="external">"Clinical manifestations and diagnosis of obesity hypoventilation syndrome", section on 'Assess complications'</a>.)</p><p class="headingAnchor" id="H1960441088"><span class="h2">High altitude</span><span class="headingEndMark"> — </span>High altitude is defined as an elevation of &gt;2500 meters above sea level. There are a paucity of data on prevalence of high-altitude PH, defined as mean pulmonary artery pressure PAP ≥30 mmHg by the International Society for Mountain Medicine with some reports suggesting rates of 5 percent or higher [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H134693666"><span class="h2">Miscellaneous</span><span class="headingEndMark"> — </span>Pulmonary developmental disorders are rare causes of PH.</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Among the etiologies of group 3 PH, the strongest evidence favors hypoxic pulmonary vasoconstriction (HPVC) with remodeling of the pulmonary vascular bed. Most of the data are derived from patients with chronic obstructive pulmonary disease (COPD), but these mechanisms are likely common among all patients with group 3 PH. However, other disease-specific mechanisms are likely also involved in the development of PH.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoxic pulmonary vasoconstriction</strong> – HPVC is a normal regulatory mechanism designed to limit blood flow to hypoxic alveoli and preserve ventilation-perfusion matching. Both alveolar hypoxia and peripheral arterial hypoxemia may contribute to HPVC, particularly high altitude PH. Its effect on pulmonary vascular pressure depends on the duration of the hypoxia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Short-term hypoxia (hours to days) causes immediate precapillary arteriole vasoconstriction, which appears to be mediated by mitochondrial signaling and ion channels in smooth muscle cells and can be fully reversed with oxygen therapy [<a href="#rid64">64-66</a>]. This type of HPVC can be seen in patients who develop intermittent hypoxemia (eg, obstructive sleep apnea) or acute hypoxemic respiratory failure; in the latter, the acute rise in pulmonary pressures can be misconstrued as due to underlying PH but they frequently resolve to baseline after treatment of the underlying cause of hypoxemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic hypoxia (days to weeks), in contrast, causes pulmonary vasoconstriction by a variety of mechanisms and is often only partially reversible [<a href="#rid67">67,68</a>]. As an example, correction of hypoxemia with supplemental oxygen in one study decreased the pulmonary vascular resistance and mean pulmonary artery pressure, but only by a small amount [<a href="#rid69">69</a>]. Mechanisms by which chronic hypoxia induce vasoconstriction include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The endogenous vasodilator, nitric oxide, decreases due to diminished endothelial nitric oxide synthase (eNOS) production and increased hemoglobin-mediated inactivation [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Production of the voltage-gated potassium channel's alpha subunit or activity of the full transmembrane protein decrease, causing the resting membrane potential to change. As a result, intracellular free calcium increases and pulmonary artery smooth muscles contract (ie, vasoconstriction) [<a href="#rid72">72-75</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cytosolic phospholipase A2 (cPLA2) activity increases, which releases arachidonic acid from phospholipid membranes. Arachidonic acid can then be metabolized by cyclooxygenases and lipoxygenases into a number of different vasoactive eicosanoids, including prostaglandins, thromboxanes, and leukotrienes.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased expression of endothelin-1 resulting in vasoconstriction, smooth muscle cell proliferation and matrix deposition  (<a class="graphic graphic_figure graphicRef81161" href="/d/graphic/81161.html" rel="external">figure 1</a>) [<a href="#rid76">76-84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular remodeling</strong> – Evidence of vascular remodeling over time can be seen pathologically. Initial changes include distal neomuscularization of the arterioles, intimal thickening, and medial hypertrophy. Abnormal collagen matrix is deposited within the adventitia later [<a href="#rid85">85,86</a>]. Eventually it is thought that this obliterative remodeling leads to fewer peripheral blood vessels and consequently increased peripheral vascular resistance seen in PH [<a href="#rid18">18-20</a>]. The varying degree to which each individual's disease is reversible may explain, in part, why the progression to severe PH is unpredictable in patients with COPD [<a href="#rid87">87-91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other mechanisms</strong> – Genetic polymorphisms may explain the significant variability in the prevalence of PH among patients with COPD. As an example, patients with hypoxemic COPD that carry the LL serotonin transporter gene polymorphism had higher mean pulmonary artery pressure (mPAP) than those with the LS or SS variant (34 mmHg versus 23 mmHg and 22 mmHg, respectively) [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">Nitric oxide, prostacyclin, thromboxane, C-reactive protein, tumor necrosis factor alpha, transforming growth factor-beta, and vascular endothelial growth factor may also play important roles in PH associated with COPD or interstitial lung disease (ILD) [<a href="#rid79">79,80,93-96</a>].</p><p></p><p class="bulletIndent1">Additional mechanisms underlying ILD-associated PH include [<a href="#rid77">77,97-99</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vascular destruction due to progressive parenchymal fibrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Vascular inflammation</p><p class="bulletIndent2"><span class="glyph">•</span>Perivascular fibrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Thrombotic angiopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Endothelial dysfunction</p><p></p><p class="bulletIndent1">Among the different ILDs, additional abnormalities may also exist:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with PH associated with idiopathic pulmonary fibrosis (IPF) may have an abnormal vascular phenotype, characterized by aberrant gene expression profiles that promote vascular remodeling [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anti-endothelial antibodies and other autoimmune processes have been implicated in the development of PH associated with connective tissue diseases (CTD; eg, systemic sclerosis) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although classified as group 5 PH, in sarcoidosis-associated PH purported mechanisms include vasculature compression by enlarged lymph nodes, sarcoidosis-related arteritis, and pulmonary veno-occlusive disease [<a href="#rid101">101-108</a>]. PH associated with pulmonary Langerhans cell histiocytosis (PLCH) has been associated with a proliferative pulmonary vasculopathy involving the muscular arteries and veins has been reported in patients with PLCH [<a href="#rid109">109</a>] which may explain why PH in this population tends to be more severe than predicted by the degree of hypoxemia or spirometric abnormality [<a href="#rid53">53,110</a>].</p><p></p><p>The mechanism of PH in patients with sleep-related breathing disorders is presumed to be due to HPVC from nocturnal events but HPVC is less well studied in this population than in patients with COPD. Daytime hypoxemia from coexistent chronic lung disease or diastolic heart failure may also contribute to the development of PH in patients with sleep-related breathing disorders [<a href="#rid3">3,91,111,112</a>]. (See  <a class="medical medical_review" href="/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults", section on 'Pulmonary hypertension'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL EVALUATION</span></p><p class="headingAnchor" id="H2432774067"><span class="h2">Suspecting group 3 pulmonary hypertension</span><span class="headingEndMark"> — </span>A high index of suspicion is needed for the detection of PH in patients with pulmonary disorders since many of the symptoms of the lung disease itself mimic those of PH (eg, exertional dyspnea, fatigue, lethargy). Features that prompt a diagnosis of PH in patients with lung disease are discussed in this section while the general signs and symptoms of PH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a>.)</p><p>During the routine evaluation of chronic lung disease or hypoxemia, patients undergo a history and physical examination, and typically also undergo imaging with chest radiography and/or computed tomography (CT), pulmonary function testing (PFT; including spirometry, lung volumes, and diffusing capacity), and occasionally lung biopsy. Other than lung biopsy, most of these tests are also routinely performed during the evaluation of patients with PH of unclear etiology, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a>.)</p><p>Importantly, evaluation should occur when patients are stable, rather than during an exacerbation of their underlying lung disease, which can temporarily increase pulmonary pressures due to hypoxic vasoconstriction.</p><p>Specific to patients with lung disease and/or hypoxemia, the following findings should prompt consideration of PH [<a href="#rid2">2,113</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Exertional dyspnea or hypoxemia that is not fully explained by the degree of parenchymal lung disease or severity of the underlying sleep disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid decline of arterial oxygenation upon exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any of the clinical features suggestive of right-sided heart failure including: exertional chest pain (eg, atypical or non-anginal chest pain), syncope or near-syncope, increased intensity of or a palpable pulmonic component of the second heart sound, a widened split second heart sound, elevated jugular venous pressure, peripheral edema, and/or electrocardiogram that demonstrates right-axis deviation, right atrial enlargement and/or right ventricular hypertrophy. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging, particularly, high resolution CT (HRCT) of the chest that demonstrates enlarged pulmonary arteries, attenuation of peripheral pulmonary vasculature, or right ventricular enlargement is suggestive of PH. Although the exact cutoff is unclear, a main pulmonary artery diameter of &gt;29 mm has been shown to have a sensitivity and specificity of 89 and 83 percent, respectively, for diagnosing PH [<a href="#rid114">114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PFTs revealing severe reductions in diffusing capacity (eg, &lt;30 percent predicted), but in particular, a diffusing capacity that is decreased out of proportion to the severity of the restrictive or obstructive defect. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung biopsy, (if done during the diagnostic evaluation of interstitial lung disease [ILD]) may incidentally reveal PH. However, this is rare and lung biopsy is not required or advisable in the setting of suspected PH.</p><p></p><p class="headingAnchor" id="H866954934"><span class="h2">Doppler echocardiography</span><span class="headingEndMark"> — </span>While investigating patients with suspected PH of unknown etiology for underlying lung disease and/or sleep disordered breathing is routine, there are minimal guidelines for clinicians for the investigation of PH in those who have known underlying lung disease, hypoxemia, and/or OSA. Nonetheless, most experts agree that it is prudent to perform an initial echocardiogram in the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients suspected to have PH based upon any of the features listed above. (See <a class="local">'Suspecting group 3 pulmonary hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with at least moderate obstructive disease on PFTs or patients with interstitial lung disease who need supplemental oxygen [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients suspected as having coexistent left-sided heart disease. (See  <a class="medical medical_review" href="/d/html/5298.html" rel="external">"Tissue Doppler echocardiography"</a>.)</p><p></p><p>Echocardiography is used to detect elevated pulmonary artery systolic pressures (ePASP) as well as altered right-sided ventricle structure or dysfunction and evidence of left-sided heart disease. However, the definition of mild, moderate, and severe PH on echocardiography is ill-defined (and the cut-offs are somewhat arbitrary). In addition, echocardiography can be misleading, particularly in those with advanced lung disease [<a href="#rid7">7,116,117</a>] (see <a class="local">'Prevalence'</a> above). With these caveats in mind, we suggest the following  (<a class="graphic graphic_table graphicRef112828" href="/d/graphic/112828.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If echocardiogram is supportive of mild PH (eg, ePASP 20 to 39 mmHg) in the absence of any other etiology for PH, then most clinicians do not proceed with right heart catheterization (RHC), but rather observe patients for progressive symptoms over time. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis", section on 'Nonsevere pulmonary hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, if PH is moderate (eg, ePASP ≥40 and &lt;60 mmHg) or severe (ePASP ≥60 mmHg, tricuspid regurgitant jet velocity &gt;3 meters/second, RV dilatation or dysfunction), then most experts refer to a center with expertise in PH to proceed with RHC to confirm the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If echocardiography does not reveal PH (eg, PASP &lt;20 mmHg), no RHC is generally done, unless the suspicion for PH is high (eg, unexplained symptoms or hypoxemia). Similarly, for those with an inadequate study in whom the suspicion is high, then many experts proceed with RHC.</p><p></p><p>Further details regarding features suggestive of PH on echocardiography are discussed separately. (See  <a class="medical medical_review" href="/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'</a>.)</p><p class="headingAnchor" id="H1548490611"><span class="h2">Additional testing</span><span class="headingEndMark"> — </span>Several additional diagnostic tests may be performed as part of the evaluation of patients with suspected PH to identify specific pulmonary etiologies as well as exclude other etiologies of PH. Additional tests include overnight oximetry (to detect nocturnal hypoxemia), polysomnography (to detect obstructive sleep apnea (OSA) only if suspected), ventilation/perfusion (V/Q) scanning and/or CT pulmonary arteriography (to detect thromboembolic disease or pulmonary artery obstructions; group 4 PH), the six-minute walk test (6MWT; to determine the World Health Organization functional class  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 3</a>)), cardiopulmonary exercise testing (may help distinguish group 3 from group 2 PH), and laboratory studies (eg, arterial blood gas, N-terminal pro-brain natriuretic peptide level, HIV serology, liver function tests, and connective tissue disease screening). (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial diagnostic evaluation (noninvasive testing)'</a>.)</p><p>Although cardiac magnetic resonance imaging (MRI) is an alternative and may be superior to echocardiography for assessment of right ventricular size, pressures, and function (ie, contractility, ejection fraction, wall motion abnormalities) [<a href="#rid118">118</a>], it is not universally available. In addition, if echocardiographic imaging was adequate, MRI is not typically performed as the result does not alter the decision to proceed with confirmatory RHC. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging"</a>.)</p><p class="headingAnchor" id="H351697707"><span class="h1">PATIENT SELECTION FOR RIGHT HEART CATHETERIZATION</span><span class="headingEndMark"> — </span>Although right heart catheterization (RHC) is the gold standard test to confirm the diagnosis of PH, not every patient requires this procedure. The choice depends upon factors including the suspected severity of PH, the potential for pulmonary arterial hypertension (PAH)-specific therapy (which is often limited in group 3 PH), the values and life expectancy of the patient, candidacy for lung transplantation or trial inclusion, suspected component of group 2 (or other) PH, and potential prognostic information. Patients in whom RHC is being considered should be referred to a center with expertise in PH.</p><p>Hemodynamic values for normal adults can be found in the table  (<a class="graphic graphic_table graphicRef70326" href="/d/graphic/70326.html" rel="external">table 4</a>). Due to exaggerated changes in intrathoracic pressure with breathing in those with significant lung disease, mean pressures should be averaged over several breaths and not during a breath hold. The definitions of PH by RHC (mean pulmonary arterial pressure [mPAP] ≥20 mmHg) and technical details regarding RHC are provided separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'</a> and  <a class="medical medical_review" href="/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a> and  <a class="medical medical_review" href="/d/html/1595.html" rel="external">"Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults"</a> and  <a class="medical medical_review" href="/d/html/1658.html" rel="external">"Pulmonary artery catheters: Insertion technique in adults"</a>.)</p><p class="headingAnchor" id="H632758895"><span class="h2">Right heart catheterization not indicated</span></p><p class="headingAnchor" id="H500620840"><span class="h3">Suspected mild pulmonary hypertension</span><span class="headingEndMark"> — </span>In patients with suspected group 3 PH, most experts will not proceed with RHC when PH is assessed as mild  (<a class="graphic graphic_table graphicRef112828" href="/d/graphic/112828.html" rel="external">table 2</a>). This may be defined as an estimated pulmonary artery systolic pressure (ePASP) 20 to 39 mmHg on echocardiography without signs of right ventricular dysfunction (see <a class="local">'Doppler echocardiography'</a> above). In such cases, a clinical diagnosis of group 3 PH can be made based upon clinical assessment and noninvasive testing. The rationale for this approach is that no additional diagnostic or therapeutic decisions would be gained from RHC, which is a procedure that carries risk. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis", section on 'Nonsevere pulmonary hypertension'</a>.)</p><p class="headingAnchor" id="H2807420991"><span class="h3">Patients with contraindications</span><span class="headingEndMark"> — </span>It is unusual that a RHC cannot be placed but contraindications include infection (particularly at the insertion site or the presence of bacteremia) and the presence of right ventricle assist device as well as irreversible coagulopathy, electrolyte disturbances and other conditions which are discussed separately. (See  <a class="medical medical_review" href="/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults", section on 'Contraindications'</a>.)</p><p class="headingAnchor" id="H1921063754"><span class="h2">Right heart catheterization is indicated</span></p><p class="headingAnchor" id="H2346978279"><span class="h3">Suspected moderate or severe pulmonary hypertension</span><span class="headingEndMark"> — </span>The value of RHC is controversial in this group, particularly in those with suspected moderate PH since <strong>many</strong> patients are <strong>not</strong> eligible for PAH-specific therapy  (<a class="graphic graphic_table graphicRef112828" href="/d/graphic/112828.html" rel="external">table 2</a>). One trial reporting some success of the PAH-specific agent, inhaled <a class="drug drug_general" data-topicid="10207" href="/d/drug information/10207.html" rel="external">treprostinil</a>, in patients with PH due to interstitial lung disease (PH-ILD) has increased the use of RHC in this population [<a href="#rid119">119</a>]. This trial is discussed separately. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis", section on 'Interstitial lung disease'</a>.)</p><p>Typically, we have a low threshold to perform RHC in the Group 3 PH population since RHC provides diagnostic and prognostic information for potential transplant candidacy and life expectancy. In our experience, most clinicians perform RHC in patients with suspected severe group 3 PH (ePASP ≥60 mmHg), while RHC may be performed on a case-by-case basis for those with suspected moderate group 3 PH (eg, estimated PASP 40 to 59 mmHg). RHC is also often performed in those with a high suspicion for severe PH in whom echocardiography is inadequate. (See <a class="local">'Doppler echocardiography'</a> above and  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis", section on 'Severe pulmonary hypertension'</a>.)</p><p class="headingAnchor" id="H2889976255"><span class="h3">Suspected alternate etiologies for pulmonary hypertension</span><span class="headingEndMark"> — </span>Patients in whom contributions from alternate etiologies for PH are suspected, should undergo RHC. In particular, those with suspected left-sided heart disease (group 2 PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 5</a>)) or patients in whom a strong vascular component (eg, group 1 PAH) is suspected (eg, mild lung disease but suspected severe PH or underlying connective tissue disease); in such cases therapeutic decisions are affected by RHC data, namely addressing heart failure or candidacy for treatment or entering a clinical trial for PAH-directed therapy.</p><p class="headingAnchor" id="H4066973850"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of chronic dyspnea and of the signs and symptoms of PH are discussed separately. (See  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial differential diagnosis'</a>.)</p><p>The causes of right ventricle dilation and/or dysfunction are shown in the tables  (<a class="graphic graphic_table graphicRef90802" href="/d/graphic/90802.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef69418" href="/d/graphic/69418.html" rel="external">table 7</a>) and can generally be distinguished on clinical assessment or are evident on echocardiography itself.</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A patient is considered to have group 3 PH when PH exists in an individual who has chronic lung disease (CLD) and/or hypoxemia, and no alternative cause of the PH can be identified. For some patients, a clinical diagnosis of group 3 PH can be made based upon clinical assessment and echocardiographic findings of PH. For others, PH can be definitively confirmed on right heart catheterization (RHC; mean pulmonary arterial pressure [mPAP] &gt;20 mmHg). The extent of investigations needed to be done to sufficiently exclude other etiologies should depend upon clinical suspicion. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'</a> and <a class="local">'Patient selection for right heart catheterization'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p>The 6<sup>th</sup> World Symposium on Pulmonary Hypertension modified their hemodynamic definition of group 3 PH with the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CLD and/or hypoxia <strong>without</strong> PH – mPAP &lt;21 mmHg, or mPAP 21 to 24 mmHg with pulmonary vascular resistance (PVR) &lt;2 Wood units (WU)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CLD and/or hypoxia <strong>with</strong> PH – mPAP 21 to 24 mmHg with PVR ≥3 WU, or mPAP 25 to 34 mmHg</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CLD and/or hypoxia <strong>with severe</strong> PH – mPAP ≥35 mmHg, or mPAP ≥25 mmHg with low cardiac index (&lt;2.0 L·min−1·m−2) or PVR &gt;5 WU [<a href="#rid120">120-122</a>]</p><p></p><p class="headingAnchor" id="H2125887218"><span class="h1">FINALIZING THE CLASSIFICATION</span><span class="headingEndMark"> — </span>Importantly, in order to classify PH as group 3, other etiologies in the differential of PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) need to be excluded, particularly evidence of significant left heart failure. In general, features that distinguish group 3 PH from others include:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of moderate to severe impairment (eg, forced expiratory volume in one second [FEV<sub>1</sub>] &lt;60 percent in patients with chronic obstructive pulmonary disease [COPD] and forced vital capacity [FVC] &lt;70 percent in patients with pulmonary fibrosis). (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic imaging (of a lung disorder) or polysomnographic findings of (a sleep-related breathing disorder) to explain PH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced breathing reserve, normal oxygen pulse, mixed venous oxygen saturation above the lower limit of normal, and an increase in the partial arterial pressure of carbon dioxide during exercise testing (particularly relevant in COPD). (See  <a class="medical medical_review" href="/d/html/3465.html" rel="external">"Cardiopulmonary exercise testing in cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of mild to moderate PH on echocardiography or right heart catheterization (RHC; mean pulmonary artery pressure [mPAP] &lt;35 mmHg). (See <a class="local">'Doppler echocardiography'</a> above.)</p><p></p><p>Since overlap syndromes are not uncommon, distinguishing group 3 from other groups is challenging  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 5</a>) [<a href="#rid4">4</a>]. For example, many patients with COPD also have left-sided heart disease (group 2/3) and some patients have components of pre-capillary disease (group 1/3; eg, systemic sclerosis). These cases are best evaluated in a center with expertise in PH where RHC  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 5</a>) is typically performed to help define contribution of select etiologies to PH as well as the contribution of PH to symptoms. (See  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Pulmonary hypertension'</a>.)</p><p>Whether similar values should be taken into account for those with high altitude PH is unclear although PH has been defined by other as mPAP ≥30mmHg [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H996498"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Patients with pulmonary hypertension (PH) due to chronic lung disease (eg, chronic obstructive pulmonary disease, interstitial lung disease, combined fibrosis and emphysema) or conditions that cause hypoxemia (eg, obstructive sleep apnea, hypoventilation syndromes) are classified as having group 3 PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). (See <a class="local">'Classification and definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The prevalence of group 3 PH varies depending upon the underlying disease and its severity with rates ranging from 20 to 90 percent. Most patients in group 3 PH have <strong>mild to moderate</strong> elevations in mean pulmonary artery pressure (eg, mPAP 25 to 34 mmHg)  (<a class="graphic graphic_table graphicRef112828" href="/d/graphic/112828.html" rel="external">table 2</a>). In contrast, to patients with group 1 pulmonary arterial hypertension (PAH), few patients in group 3 PH (&lt;5 percent) have severe PH (mPAP ≥35 mmHg or mPAP ≥25 mmHg, and elevated right atrial pressure and/or a cardiac index &lt;2 L/min/m<sup>2</sup>). The severity of PH appears to correlate with the severity of the underlying disorder. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Hypoxic pulmonary vasoconstriction with remodeling of the pulmonary vascular bed are common mechanisms that underlie the development of PH in patients with chronic lung disorders and/or hypoxemia. However, other mechanisms are likely also involved. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical evaluation</strong> – A high index of suspicion for PH should be maintained and Doppler echocardiography performed in patients with chronic lung disorders and/or hypoxemia who have the following (See <a class="local">'Clinical evaluation'</a> above and <a class="local">'Suspecting group 3 pulmonary hypertension'</a> above.):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exertional dyspnea or hypoxemia disproportionate to the severity of the underlying lung or sleep disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Features suggestive of right-sided heart failure</p><p class="bulletIndent2"><span class="glyph">•</span>Enlarged pulmonary artery or right ventricle on imaging</p><p class="bulletIndent2"><span class="glyph">•</span>Severe reduction in diffusing capacity (especially one that is decreased out of proportion to the severity of the restrictive or obstructive defect)</p><p></p><p class="bulletIndent1">Echocardiography should also be performed in patients with at least moderate obstructive disease and patients with interstitial lung disease who need supplemental oxygen as well as in patients suspected as having coexistent left-sided heart disease. Additional testing may be performed to rule out other competing or contributing etiologies or to help narrow the differential. (See <a class="local">'Doppler echocardiography'</a> above and <a class="local">'Additional testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Right heart catheter indications</strong> – Selecting patients for right heart catheterization (RHC) depends upon factors including the suspected severity of PH, the potential for PAH-specific therapy, the values and life expectancy of the patient, candidacy for lung transplantation or trial inclusion, suspected component of group 2 (or other) PH, and potential prognostic information. (See <a class="local">'Patient selection for right heart catheterization'</a> above.)</p><p></p><p class="bulletIndent1">In general, patients suspected to have severe group 3 PH or an alternate class should undergo RHC, while patients suspected to have mild PH or who have contraindications do not need RHC until PH progresses or the contraindication resolves; RHC in patients with suspected moderate PH should be considered on a case-by-case basis. Patients in whom RHC is being considered should be referred to a center with expertise in PH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A patient is considered to be in group 3 when PH exists in an individual who has chronic lung disease and/or hypoxemia, and <strong>no alternative</strong> cause of the PH can be identified. For some patients, a clinical diagnosis can be made based upon clinical assessment and echocardiographic findings. For others, PH can be definitively confirmed on RHC (mPAP &gt;20 mmHg). The extent of investigations needed to be done to sufficiently exclude other etiologies should be depend upon clinical suspicion. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med 2003; 24:233.</a></li><li><a class="nounderline abstract_t">Pugh ME, Sivarajan L, Wang L, et al. Causes of pulmonary hypertension in the elderly. Chest 2014; 146:159.</a></li><li><a class="nounderline abstract_t">Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:549.</a></li><li><a class="nounderline abstract_t">Falk JA, Kadiev S, Criner GJ, et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:543.</a></li><li><a class="nounderline abstract_t">Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167:735.</a></li><li><a class="nounderline abstract_t">Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32:1371.</a></li><li><a class="nounderline abstract_t">Vizza CD, Lynch JP, Ochoa LL, et al. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998; 113:576.</a></li><li><a class="nounderline abstract_t">Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531.</a></li><li><a class="nounderline abstract_t">Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166:314.</a></li><li><a class="nounderline abstract_t">Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104:1877.</a></li><li><a class="nounderline abstract_t">Burrows B, Kettel LJ, Niden AH, et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286:912.</a></li><li><a class="nounderline abstract_t">Weitzenblum E, Hirth C, Ducolone A, et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36:752.</a></li><li><a class="nounderline abstract_t">Doi M, Nakano K, Hiramoto T, Kohno N. Significance of pulmonary artery pressure in emphysema patients with mild-to-moderate hypoxemia. Respir Med 2003; 97:915.</a></li><li><a class="nounderline abstract_t">Higham MA, Dawson D, Joshi J, et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. Eur Respir J 2001; 17:350.</a></li><li><a class="nounderline abstract_t">Fayngersh V, Drakopanagiotakis F, Dennis McCool F, Klinger JR. Pulmonary hypertension in a stable community-based COPD population. Lung 2011; 189:377.</a></li><li><a class="nounderline abstract_t">Oswald-Mammosser M, Apprill M, Bachez P, et al. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration 1991; 58:304.</a></li><li><a class="nounderline abstract_t">Christensen CC, Ryg MS, Edvardsen A, Skjønsberg OH. Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients. Eur Respir J 2004; 24:580.</a></li><li><a class="nounderline abstract_t">Kessler R, Faller M, Weitzenblum E, et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164:219.</a></li><li><a class="nounderline abstract_t">Raghu G, Nathan SD, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015; 46:1370.</a></li><li><a class="nounderline abstract_t">Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746.</a></li><li><a class="nounderline abstract_t">Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30:715.</a></li><li><a class="nounderline abstract_t">Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131:657.</a></li><li><a class="nounderline abstract_t">Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128:2393.</a></li><li><a class="nounderline abstract_t">Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16:460.</a></li><li><a class="nounderline abstract_t">Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170:360.</a></li><li><a class="nounderline abstract_t">McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:14S.</a></li><li><a class="nounderline abstract_t">Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002; 19:571.</a></li><li><a class="nounderline abstract_t">Rayner CF, Grubnic S. Pulmonary manifestations of systemic autoimmune disease. Best Pract Res Clin Rheumatol 2004; 18:381.</a></li><li><a class="nounderline abstract_t">Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110:1515.</a></li><li><a class="nounderline abstract_t">Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425.</a></li><li><a class="nounderline abstract_t">MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453.</a></li><li><a class="nounderline abstract_t">Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002; 45:225.</a></li><li><a class="nounderline abstract_t">Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005; 44:366.</a></li><li><a class="nounderline abstract_t">Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30:2398.</a></li><li><a class="nounderline abstract_t">Rhee RL, Gabler NB, Sangani S, et al. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2015; 192:1111.</a></li><li><a class="nounderline abstract_t">Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125.</a></li><li><a class="nounderline abstract_t">Rosenman KD, Zhu Z. Pneumoconiosis and associated medical conditions. Am J Ind Med 1995; 27:107.</a></li><li><a class="nounderline abstract_t">Tomasini M, Chiappino G. Hemodynamics of pulmonary circulation in asbestosis: study of 16 cases. Am J Ind Med 1981; 2:167.</a></li><li><a class="nounderline abstract_t">Scano G, Garcia-Herreros P, Stendardi D, et al. Cardiopulmonary adaptation to exercise in coal miners. Arch Environ Health 1980; 35:360.</a></li><li><a class="nounderline abstract_t">Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141:222.</a></li><li><a class="nounderline abstract_t">Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136:10.</a></li><li><a class="nounderline abstract_t">Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35:105.</a></li><li><a class="nounderline abstract_t">Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233.</a></li><li><a class="nounderline abstract_t">Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129:1246.</a></li><li><a class="nounderline abstract_t">Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25:783.</a></li><li><a class="nounderline abstract_t">Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111:278.</a></li><li><a class="nounderline abstract_t">Rapti A, Kouranos V, Gialafos E, et al. Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung 2013; 191:61.</a></li><li><a class="nounderline abstract_t">Alhamad EH, Idrees MM, Alanezi MO, et al. Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients. Ann Thorac Med 2010; 5:86.</a></li><li><a class="nounderline abstract_t">Huitema MP, Bakker ALM, Mager JJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J 2019; 54.</a></li><li><a class="nounderline abstract_t">Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68.</a></li><li><a class="nounderline abstract_t">Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79:1269.</a></li><li><a class="nounderline abstract_t">Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379:537.</a></li><li><a class="nounderline abstract_t">Manika K, Pitsiou GG, Boutou AK, et al. The Impact of Pulmonary Arterial Pressure on Exercise Capacity in Mild-to-Moderate Cystic Fibrosis: A Case Control Study. Pulm Med 2012; 2012:252345.</a></li><li><a class="nounderline abstract_t">Oliveira RK, Pereira CA, Ramos RP, et al. A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. Eur Respir J 2014; 44:415.</a></li><li><a class="nounderline abstract_t">Pullamsetti SS, Kojonazarov B, Storn S, et al. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med 2017; 9.</a></li><li><a class="nounderline abstract_t">Ismail K, Roberts K, Manning P, et al. OSA and pulmonary hypertension: time for a new look. Chest 2015; 147:847.</a></li><li><a class="nounderline abstract_t">Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104:1300.</a></li><li><a class="nounderline abstract_t">Chaouat A, Weitzenblum E, Krieger J, et al. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996; 109:380.</a></li><li><a class="nounderline abstract_t">Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.</a></li><li><a class="nounderline abstract_t">León-Velarde F, Maggiorini M, Reeves JT, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005; 6:147.</a></li><li><a class="nounderline abstract_t">Mirrakhimov AE, Strohl KP. High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management. Open Cardiovasc Med J 2016; 10:19.</a></li><li><a class="nounderline abstract_t">Weissmann N, Ebert N, Ahrens M, et al. Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs. Am J Respir Cell Mol Biol 2003; 29:721.</a></li><li><a class="nounderline abstract_t">Mauban JR, Remillard CV, Yuan JX. Hypoxic pulmonary vasoconstriction: role of ion channels. J Appl Physiol (1985) 2005; 98:415.</a></li><li><a class="nounderline abstract_t">Klinger JR. Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. Cardiol Clin 2016; 34:413.</a></li><li><a class="nounderline abstract_t">Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000; 105:1555.</a></li><li><a class="nounderline abstract_t">Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.</a></li><li><a class="nounderline abstract_t">Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.</a></li><li><a class="nounderline abstract_t">McQuillan LP, Leung GK, Marsden PA, et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994; 267:H1921.</a></li><li><a class="nounderline abstract_t">Defouilloy C, Teiger E, Sediame S, et al. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. Am J Respir Crit Care Med 1998; 157:1452.</a></li><li><a class="nounderline abstract_t">Wang J, Juhaszova M, Rubin LJ, Yuan XJ. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997; 100:2347.</a></li><li><a class="nounderline abstract_t">Gelband CH, Gelband H. Ca2+ release from intracellular stores is an initial step in hypoxic pulmonary vasoconstriction of rat pulmonary artery resistance vessels. Circulation 1997; 96:3647.</a></li><li><a class="nounderline abstract_t">Post JM, Hume JR, Archer SL, Weir EK. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992; 262:C882.</a></li><li><a class="nounderline abstract_t">Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304:1582.</a></li><li><a class="nounderline abstract_t">Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732.</a></li><li><a class="nounderline abstract_t">Hopkins N, McLoughlin P. The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis? J Anat 2002; 201:335.</a></li><li><a class="nounderline abstract_t">MacLean MR. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J Lab Clin Med 1999; 134:105.</a></li><li><a class="nounderline abstract_t">Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22:405.</a></li><li><a class="nounderline abstract_t">Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109:159.</a></li><li><a class="nounderline abstract_t">Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 2005; 45:182.</a></li><li><a class="nounderline abstract_t">Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 2004; 34:442.</a></li><li><a class="nounderline abstract_t">Trakada G, Nikolaou E, Pouli A, et al. Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 2003; 7:111.</a></li><li><a class="nounderline abstract_t">Yamakami T, Taguchi O, Gabazza EC, et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. Eur Respir J 1997; 10:2055.</a></li><li><a class="nounderline abstract_t">Vender RL. Chronic hypoxic pulmonary hypertension. Cell biology to pathophysiology. Chest 1994; 106:236.</a></li><li><a class="nounderline abstract_t">Tozzi CA, Poiani GJ, Harangozo AM, et al. Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium. J Clin Invest 1989; 84:1005.</a></li><li><a class="nounderline abstract_t">Weir EK, Tucker A, Reeves JT, et al. The genetic factor influencing pulmonary hypertension in cattle at high altitude. Cardiovasc Res 1974; 8:745.</a></li><li><a class="nounderline abstract_t">Nattie EE, Doble EA. Threshold of intermittent hypoxia-induced right ventricular hypertrophy in the rat. Respir Physiol 1984; 56:253.</a></li><li><a class="nounderline abstract_t">Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest 1991; 99:715.</a></li><li><a class="nounderline abstract_t">Ashutosh K, Mead G, Dunsky M. Early effects of oxygen administration and prognosis in chronic obstructive pulmonary disease and cor pulmonale. Am Rev Respir Dis 1983; 127:399.</a></li><li><a class="nounderline abstract_t">Weitzenblum E, Schrijen F, Mohan-Kumar T, et al. Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis. Chest 1988; 94:772.</a></li><li><a class="nounderline abstract_t">Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108:1839.</a></li><li><a class="nounderline abstract_t">Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006; 130:326.</a></li><li><a class="nounderline abstract_t">Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991; 88:6642.</a></li><li><a class="nounderline abstract_t">Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104:790.</a></li><li><a class="nounderline abstract_t">Koyama S, Sato E, Haniuda M, et al. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166:382.</a></li><li><a class="nounderline abstract_t">Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11:452.</a></li><li><a class="nounderline abstract_t">Mura M, Anraku M, Yun Z, et al. Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. Chest 2012; 141:661.</a></li><li><a class="nounderline abstract_t">Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21:467.</a></li><li><a class="nounderline abstract_t">Gagermeier J, Dauber J, Yousem S, et al. Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension. Chest 2005; 128:601S.</a></li><li><a class="nounderline abstract_t">Toonkel RL, Borczuk AC, Pearson GD, et al. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration 2010; 79:341.</a></li><li><a class="nounderline abstract_t">Hamilton-Craig CR, Slaughter R, McNeil K, et al. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ 2009; 18:222.</a></li><li><a class="nounderline abstract_t">Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23:1216.</a></li><li><a class="nounderline abstract_t">Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990; 97:500.</a></li><li><a class="nounderline abstract_t">Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3:403.</a></li><li><a class="nounderline abstract_t">Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134:809.</a></li><li><a class="nounderline abstract_t">Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.</a></li><li><a class="nounderline abstract_t">Angomachalelis N, Hourzamanis A, Vamvalis C, Gavrielides A. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J 1992; 68 Suppl 1:S52.</a></li><li><a class="nounderline abstract_t">Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161:216.</a></li><li><a class="nounderline abstract_t">Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest 1997; 111:1142.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250.</a></li><li><a class="nounderline abstract_t">Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131:835.</a></li><li><a class="nounderline abstract_t">Dauriat G, Reynaud-Gaubert M, Cottin V, et al. Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. J Heart Lung Transplant 2021; 40:1009.</a></li><li><a class="nounderline abstract_t">Corson N, Armato SG 3rd, Labby ZE, et al. CT-based pulmonary artery measurements for the assessment of pulmonary hypertension. Acad Radiol 2014; 21:523.</a></li><li><a class="nounderline abstract_t">Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest 2017; 151:204.</a></li><li><a class="nounderline abstract_t">D'Andrea A, Stanziola A, Di Palma E, et al. Right Ventricular Structure and Function in Idiopathic Pulmonary Fibrosis with or without Pulmonary Hypertension. Echocardiography 2016; 33:57.</a></li><li><a class="nounderline abstract_t">Nowak J, Hudzik B, Jastrzȩbski D, et al. Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation. Clin Respir J 2018; 12:930.</a></li><li><a class="nounderline abstract_t">Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 52:1683.</a></li><li><a class="nounderline abstract_t">Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021; 384:325.</a></li><li><a class="nounderline abstract_t">Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li></ol></div><div id="topicVersionRevision">Topic 8262 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545980" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary hypertension in chronic lung disease and hypoxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088545" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cor pulmonale: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480915" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Causes of pulmonary hypertension in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18453370" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comorbidities in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18453369" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiac disease in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480614" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978137" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pulmonary hypertension in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9515827" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Right and left ventricular dysfunction in patients with severe pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888824" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153963" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hemodynamic characterization of patients with severe emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547449" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Categorization and impact of pulmonary hypertension in patients with advanced COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5013974" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Patterns of cardiovascular dysfunction in chronic obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7330793" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12924518" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Significance of pulmonary artery pressure in emphysema patients with mild-to-moderate hypoxemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405510" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814783" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary hypertension in a stable community-based COPD population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1792422" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459136" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11463591" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250495" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537877" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17626111" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356077" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236900" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154958" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087298" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249493" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11936539" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pulmonary hypertension in collagen vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15158747" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary manifestations of systemic autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989070" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence of pulmonary hypertension in limited and diffuse scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10733441" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312386" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525998" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulmonary hypertension associated with connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561735" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14677184" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26291092" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15986394" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7900728" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pneumoconiosis and associated medical conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7349043" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hemodynamics of pulmonary circulation in asbestosis: study of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7458418" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiopulmonary adaptation to exercise in coal miners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215830" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combined pulmonary fibrosis and emphysema syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225068" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643948" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114364" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outcomes for patients with sarcoidosis awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685015" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863633" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290599" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229755" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20582173" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31320453" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227329" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473409" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240409" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical features of paediatric pulmonary hypertension: a registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22900167" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Impact of Pulmonary Arterial Pressure on Exercise Capacity in Mild-to-Moderate Cystic Fibrosis: A Case Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24743965" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141888" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732450" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : OSA and pulmonary hypertension: time for a new look.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840581" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8620709" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502631" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16060849" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Consensus statement on chronic and subacute high altitude diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27014374" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791676" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591311" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypoxic pulmonary vasoconstriction: role of ion channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27443138" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841514" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539918" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776858" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526714" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603123" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9410914" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396467" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ca2+ release from intracellular stores is an initial step in hypoxic pulmonary vasoconstriction of rat pulmonary artery resistance vessels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1566816" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7231503" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8497283" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12430958" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10444023" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590837" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The pathobiology of pulmonary hypertension. Endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734504" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Endothelial dysfunction in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654268" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Endothelin receptor antagonists: clinical realities and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305243" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Endothelin and pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569522" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Endothelin-1 levels in interstitial lung disease patients during sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311502" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020277" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Chronic hypoxic pulmonary hypertension. Cell biology to pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2668338" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4457227" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The genetic factor influencing pulmonary hypertension in cattle at high altitude.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6235562" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Threshold of intermittent hypoxia-induced right ventricular hypertrophy in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1995228" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6838047" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Early effects of oxygen administration and prognosis in chronic obstructive pulmonary disease and cor pulmonale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139371" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530202" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899829" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Systemic inflammation in patients with COPD and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1862087" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502704" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153975" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093821" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pulmonary hypertension in interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835902" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2186993" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The pulmonary pathologic manifestations of the CREST syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16373857" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797887" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378190" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1427751" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2298084" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2365034" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767134" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Sarcoidosis simulating pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348196" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1409217" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619823" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Severe pulmonary hypertension in histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106608" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332472" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4003933" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34218966" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24594422" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : CT-based pulmonary artery measurements for the assessment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27554299" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096076" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Right Ventricular Structure and Function in Idiopathic Pulmonary Fibrosis with or without Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052583" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007687" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33440084" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33986032" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Elevated pulmonary vascular resistance predicts mortality in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34385266" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
